The AMR business (Part I)
Antibiotic developers struggle with uncertain market conditions, weak reimbursement schemes and low turnover once a drug is approved. Experts are trying to figure out the best way to balance push and pull incentives.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2212 entries already.
Entries by Thomas Gabrielczyk
Researchers target ferroptosis resistance of cancer cells
German researchers have found a novel way to induce iron-induced necrosis, a process which they want to turn against cancer.
CHMP selects drugs for EU market approval
EMA’s human medicines committee (CHMP) recommended seven medicines for approval at its October 2019 meeting.
New risk factor for autism and epilepsy identified
A molecular transporter is critical for the proper maturation of neurons underlying neurodevelopmental disorders.
Healx Ltd raises $56m in Series B financing
AI-driven drug repurposing company Healx Ltd (Cambridge, UK) raises US$56m in a Series B financing and launches global accelerator programme for orphan diseases.
4SC expands domatinostat combo testing
The Netherlands Cancer Institute (NKI) has joined 4SC AG as a partner in conducting a multicentre study of dominatostat/checkpoint blocker combos in treatment-naive melanoma patients.
Cell transdifferentiation specialist Mogrify Ltd raises US$16m
British start-up company Mogrify Ltd (Cambridge, UK) has added US$16m from a Series A round to its US$3.7m seed financing in February 2019. Existing investor Ahren Innovation Capital led the round, with Parkwalk, 24Haymarket, and the University of Bristol Enterprise Fund III participating.
Patient’s organoids predict response to chemotherapy
A new test based on tumour organoids can predict how patients with advanced colorectal cancer respond to chemotherapy treatment.
ADC Therapeutics enters licence option deal with Avacta Group
ADC Therapeutics SA has entered a R&D pact with Affimer developer Avacta Group plc aimed at creating and licencing Affimer drug conjugates.
Novo Nordisk enters haemophilia gene therapy field
Licencing bluebird bio’s Inc know-how and technology in one-time gene therapies, Novo Nordisk A/S tries to get a foothold in the emerging haemophilia A gene therapy market.